These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 29935271)

  • 1. Modulation of heat shock proteins by statins.
    Forouzanfar F; Butler AE; Banach M; Barreto GE; Sahbekar A
    Pharmacol Res; 2018 Aug; 134():134-144. PubMed ID: 29935271
    [TBL] [Abstract][Full Text] [Related]  

  • 2. HMG-CoA reductase inhibitors and the kidney.
    Campese VM; Park J
    Kidney Int; 2007 Jun; 71(12):1215-22. PubMed ID: 17495867
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Statin intolerance: why and what to do - with a focus on diabetic people.
    Matteucci E; Giampietro O
    Curr Med Chem; 2013; 20(11):1397-408. PubMed ID: 23394553
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Time to improve statin prescription guidelines in low-risk patients?
    Balder JW; de Vries JK; Mulder DJ; Kamphuisen PW
    Eur J Prev Cardiol; 2017 Jul; 24(10):1064-1070. PubMed ID: 28429651
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Drug insight: the role of statins in combination with ezetimibe to lower LDL cholesterol.
    Gotto AM; Farmer JA
    Nat Clin Pract Cardiovasc Med; 2006 Dec; 3(12):664-72. PubMed ID: 17122799
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cross-talk between statins and PPARalpha in cardiovascular diseases: clinical evidence and basic mechanisms.
    Paumelle R; Staels B
    Trends Cardiovasc Med; 2008 Apr; 18(3):73-8. PubMed ID: 18436144
    [TBL] [Abstract][Full Text] [Related]  

  • 7. REVIEW: Efficacy and mechanisms of action of statins in the treatment of diabetic dyslipidemia.
    Ginsberg HN
    J Clin Endocrinol Metab; 2006 Feb; 91(2):383-92. PubMed ID: 16291700
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Emerging views of statin pleiotropy and cholesterol lowering.
    Yu D; Liao JK
    Cardiovasc Res; 2022 Jan; 118(2):413-423. PubMed ID: 33533892
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Fibrate therapy in the management of dyslipidemias, alone and in combination with statins: role of delayed-release fenofibric acid.
    Schima SM; Maciejewski SR; Hilleman DE; Williams MA; Mohiuddin SM
    Expert Opin Pharmacother; 2010 Apr; 11(5):731-8. PubMed ID: 20210682
    [TBL] [Abstract][Full Text] [Related]  

  • 10. HMG-CoA reductase inhibitors and the kidney.
    Campese VM; Hadaya B; Chiu J
    Curr Hypertens Rep; 2005 Oct; 7(5):337-42. PubMed ID: 16157074
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Dyslipidemias and statins: from guidelines to clinical practice. An updated review of the literature].
    Lucchi T; Vergani C
    G Ital Cardiol (Rome); 2014 Mar; 15(3):149-60. PubMed ID: 24770428
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Strategies to Overcome Residual Risk During Statins Era.
    Cho KI; Yu J; Hayashi T; Han SH; Koh KK
    Circ J; 2019 Sep; 83(10):1973-1979. PubMed ID: 31391351
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Novel 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors: a patent review.
    Pfefferkorn JA
    Expert Opin Ther Pat; 2011 Feb; 21(2):187-203. PubMed ID: 21214503
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cholesterol levels and statin use in patients with coronary heart disease treated in primary care settings.
    O'Connor PJ; Gray RJ; Maciosek MV; Fillbrandt KM; DeFor TA; Alexander CM; Weiss TW; Teutsch SM
    Prev Chronic Dis; 2005 Jul; 2(3):A05. PubMed ID: 15963307
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The safety and effectiveness of statins as treatment for HIV-dyslipidemia: the evidence so far and the future challenges.
    Ahmed MH; Al-Atta A; Hamad MA
    Expert Opin Pharmacother; 2012 Sep; 13(13):1901-9. PubMed ID: 22770622
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Statins.
    Ratchford EV; Martin SS
    Vasc Med; 2017 Oct; 22(5):442-445. PubMed ID: 28803537
    [No Abstract]   [Full Text] [Related]  

  • 17. Benefits of lipid-lowering therapy in patients with type 2 diabetes mellitus.
    Betteridge J
    Am J Med; 2005 Dec; 118 Suppl 12A():10-5. PubMed ID: 16356802
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Statin-associated incident diabetes: a literature review.
    Park ZH; Juska A; Dyakov D; Patel RV
    Consult Pharm; 2014; 29(5):317-34. PubMed ID: 24849689
    [TBL] [Abstract][Full Text] [Related]  

  • 19. New treatment options for lipid-lowering therapy in subjects with type 2 diabetes.
    Scicali R; Di Pino A; Ferrara V; Urbano F; Piro S; Rabuazzo AM; Purrello F
    Acta Diabetol; 2018 Mar; 55(3):209-218. PubMed ID: 29260404
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Lipid-lowering cardiovascular prevention in type 2-diabetes. Statins are effective according to the FIELD study].
    Båvenholm P; Attvall S; Nilsson PM
    Lakartidningen; 2006 Aug 30-Sep 5; 103(35):2462-6. PubMed ID: 17002161
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.